Ascendis Pharma A/S (ASND) News Today $211.17 +1.62 (+0.77%) As of 10:49 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ASND Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent October 2025 September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 Time Period Ascendis Pharma A/S (NASDAQ:ASND) Receives Consensus Recommendation of "Moderate Buy" from AnalystsOctober 11 at 5:09 AM | marketbeat.comJPMorgan Chase & Co. Forecasts Strong Price Appreciation for Ascendis Pharma A/S (NASDAQ:ASND) StockOctober 10 at 10:36 AM | marketbeat.comJP Morgan Maintains Ascendis Pharma A (ASND) Overweight RecommendationOctober 10 at 3:47 AM | msn.comAscendis Pharma A/S's (ASND) Sell (D-) Rating Reiterated at Weiss RatingsOctober 9, 2025 | marketbeat.comAscendis Pharma submits TransCon CNP marketing authorization application to EMAOctober 8, 2025 | msn.comAscendis Submits Marketing Authorisation Application to the European Medicines Agency for TransCon® CNP for Treatment of Children with AchondroplasiaOctober 8, 2025 | globenewswire.comAscendis Pharma A/S $ASND Stake Trimmed by Matisse CapitalOctober 8, 2025 | marketbeat.comAscendis Pharma A/S (NASDAQ:ASND) Sets New 1-Year High - Here's What HappenedOctober 6, 2025 | marketbeat.comCan UBS’s Backing of Yorvipath Signal a Durable Edge for Ascendis Pharma (ASND) in Rare Disease?October 4, 2025 | finance.yahoo.comUBS Maintains Buy on Ascendis (ASND), Sees Upside from Yorvipath DataOctober 2, 2025 | msn.comAscendis Pharma Closes Warrant Exercise Window, Boosts Share CapitalSeptember 30, 2025 | tipranks.comAscendis Pharma A/S $ASND Shares Sold by Toth Financial Advisory CorpSeptember 22, 2025 | marketbeat.comMorgan Stanley Sticks to Its Buy Rating for Ascendis Pharma (ASND)September 19, 2025 | theglobeandmail.comBank of America Securities Keeps Their Buy Rating on Ascendis Pharma (ASND)September 19, 2025 | theglobeandmail.comAscendis Pharma A/S $ASND Position Trimmed by Harbor Capital Advisors Inc.September 17, 2025 | marketbeat.comAscendis Pharma A/S (NASDAQ:ASND) Given Consensus Rating of "Buy" by AnalystsSeptember 17, 2025 | marketbeat.comGoldman Sachs Group Inc. Boosts Holdings in Ascendis Pharma A/S $ASNDSeptember 15, 2025 | marketbeat.comMorgan Stanley Remains Bullish on Ascendis Pharma (ASND)September 14, 2025 | msn.comVident Advisory LLC Buys Shares of 1,750 Ascendis Pharma A/S $ASNDSeptember 12, 2025 | marketbeat.comWoodline Partners LP Sells 12,836 Shares of Ascendis Pharma A/S $ASNDSeptember 11, 2025 | marketbeat.comZimmer Partners LP Has $5.63 Million Stock Holdings in Ascendis Pharma A/S $ASNDSeptember 11, 2025 | marketbeat.comFred Alger Management LLC Has $10.10 Million Stake in Ascendis Pharma A/S $ASNDSeptember 11, 2025 | marketbeat.comAscendis Pharma A/S (NASDAQ:ASND) Sets New 12-Month High - Still a Buy?September 10, 2025 | marketbeat.comAscendis Pharma A/S $ASND Shares Sold by Alliancebernstein L.P.September 9, 2025 | marketbeat.com$100 Invested In Ascendis Pharma 10 Years Ago Would Be Worth This Much TodaySeptember 9, 2025 | benzinga.comAlyeska Investment Group L.P. Trims Stake in Ascendis Pharma A/S $ASNDSeptember 8, 2025 | marketbeat.comCinctive Capital Management LP Makes New Investment in Ascendis Pharma A/S $ASNDSeptember 7, 2025 | marketbeat.comDuquesne Family Office LLC Trims Position in Ascendis Pharma A/S $ASNDSeptember 6, 2025 | marketbeat.comAdage Capital Partners GP L.L.C. Acquires Shares of 327,405 Ascendis Pharma A/S $ASNDSeptember 6, 2025 | marketbeat.comJump Financial LLC Sells 10,644 Shares of Ascendis Pharma A/S $ASNDSeptember 6, 2025 | marketbeat.comADAR1 Capital Management LLC Lowers Stock Position in Ascendis Pharma A/S $ASNDSeptember 5, 2025 | marketbeat.comHere's How Much $100 Invested In Ascendis Pharma 10 Years Ago Would Be Worth TodaySeptember 4, 2025 | benzinga.comAscendis Pharma A/S (NASDAQ:ASND) Reaches New 52-Week High After Analyst UpgradeSeptember 4, 2025 | marketbeat.comBank of America Issues Positive Forecast for Ascendis Pharma A/S (NASDAQ:ASND) Stock PriceSeptember 4, 2025 | marketbeat.comVestal Point Capital LP Lowers Stock Position in Ascendis Pharma A/S $ASNDSeptember 4, 2025 | marketbeat.comRA Capital Management L.P. Purchases 168,752 Shares of Ascendis Pharma A/S $ASNDSeptember 4, 2025 | marketbeat.comAscendis Pharma A/S (ASND) Presents at Wells Fargo 20th Annual Healthcare Conference 2025 TranscriptSeptember 3, 2025 | seekingalpha.comAscendis to Share Latest Endocrinology Rare Disease Data in 3 Oral Presentations at ASBMR 2025September 3, 2025 | finance.yahoo.comBraidwell LP Buys New Position in Ascendis Pharma A/S $ASNDSeptember 3, 2025 | marketbeat.com12,053 Shares in Ascendis Pharma A/S $ASND Acquired by Point72 Europe London LLPSeptember 3, 2025 | marketbeat.comQuarry LP Purchases 2,600 Shares of Ascendis Pharma A/S $ASNDSeptember 3, 2025 | marketbeat.comAscendis to Share Latest Endocrinology Rare Disease Data in 3 Oral Presentations at ASBMR 2025September 2, 2025 | globenewswire.comTrexquant Investment LP Raises Stake in Ascendis Pharma A/S $ASNDSeptember 2, 2025 | marketbeat.comHsbc Holdings PLC Makes New Investment in Ascendis Pharma A/S $ASNDSeptember 2, 2025 | marketbeat.comAscendis Pharma A/S $ASND Shares Bought by Driehaus Capital Management LLCSeptember 1, 2025 | marketbeat.comAscendis Pharma A/S $ASND Stock Position Decreased by Siren L.L.C.August 31, 2025 | marketbeat.comTema Etfs LLC Has $952,000 Stock Position in Ascendis Pharma A/S $ASNDAugust 30, 2025 | marketbeat.com32,325 Shares in Ascendis Pharma A/S $ASND Purchased by Tri Locum Partners LPAugust 30, 2025 | marketbeat.comAscendis Pharma to Participate in the 2025 Wells Fargo Healthcare ConferenceAugust 28, 2025 | finance.yahoo.comAscendis Pharma to Participate in the 2025 Wells Fargo Healthcare ConferenceAugust 28, 2025 | globenewswire.com Get Ascendis Pharma A/S News Delivered to You Automatically Sign up to receive the latest news and ratings for ASND and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ASND Media Mentions By Week ASND Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ASND News Sentiment▼0.680.77▲Average Medical News Sentiment ASND News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ASND Articles This Week▼118▲ASND Articles Average Week Get the Latest News and Ratings for ASND and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Ascendis Pharma A/S and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies ARGX News Today TAK News Today ONC News Today INSM News Today BNTX News Today TEVA News Today GMAB News Today SMMT News Today VTRS News Today RDY News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ASND) was last updated on 10/13/2025 by MarketBeat.com Staff From Our PartnersURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | Sponsored2013 miner reveals his trading systemWhile everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | Sponsored$3,600 gold is nice ... but here’s what most gold bugs are missingGold just surged past $3,600, but Weiss Ratings expert Sean Brodrick says the real upside is in select gold st...Weiss Ratings | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ascendis Pharma A/S Please log in to your account or sign up in order to add this asset to your watchlist. Share Ascendis Pharma A/S With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
